Felix Y. Feng

Felix Y. Feng

Auto-generated profile, based on publicly available information

Felix Y. Feng

Department of Radiation Oncology, University of California San Francisco , San Francisco, CA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Cell
Verified
Journal Article
Closed access
DQDavid A. Quigley
David A. Quigley
HDHa X. Dang
Ha X. Dang
SZShuang G. Zhao
Shuang G. Zhao
PLPaul Lloyd
Paul Lloyd
RARahul Aggarwal
Rahul Aggarwal
FFFelix Y. Feng
Felix Y. Feng

13 July 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SZShuang G. Zhao
Shuang G. Zhao
WCWilliam S. Chen
William S. Chen
HLHaolong Li
Haolong Li
AFAdam Foye
Adam Foye
MZMeng Zhang
Meng Zhang
FFFelix Y. Feng
Felix Y. Feng

10 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HSHanbing Song
Hanbing Song
HWHannah N. W. Weinstein
Hannah N. W. Weinstein
PAPaul Allegakoen
Paul Allegakoen
MWMarc H. Wadsworth
Marc H. Wadsworth
JXJamie Xie
Jamie Xie
FHFranklin Huang
Franklin Huang
Prostate cancer is the second most common malignancy in men worldwide and consists of a mixture of tumor and non-tumor cell types. To characterize the prostate cancer tumor microenvironment, we perform single-cell RNA-sequencing on prostate biopsies, prostatectomy specimens, and patient-derived organoids from localized prostate cancer patients. We uncover heterogeneous cellular states in prostate epithelial cells marked by high androgen signaling states that are enriched in prostate cancer and identify a population of tumor-associated club cells that may be associated with prostate carcinogenesis. ERG-negative tumor cells, compared to ERG-positive cells, demonstrate shared heterogeneity with surrounding luminal epithelial cells and appear to give rise to common tumor microenvironment responses. Finally, we show that prostate epithelial organoids harbor tumor-associated epithelial cell states and are enriched with distinct cell types and states from their parent tissues. Our results provide diagnostically relevant insights and advance our understanding of the cellular states associated with prostate carcinogenesis.

1 December 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
SZShuang G. Zhao
Shuang G. Zhao
SCS. Laura Chang
S. Laura Chang
NENicholas Erho
Nicholas Erho
MYMenggang Yu
Menggang Yu
JLJonathan Lehrer
Jonathan Lehrer
FFFelix Y. Feng
Felix Y. Feng
The lineage of prostate cancer is unknown. Prostate cancer was first thought to derive from glandular luminal cells; however, there is mounting evidence that basal cells may also play a role in prostate carcinogenesis.1 Mouse models have demonstrated that both luminal and basal cells include self-sustaining lineages that can give rise to prostate cancer.2 Recent work has sought to characterize luminal3 and basal4 cells that display characteristics similar to those of stem cells. However, this is an area of active research, and the similarities and differences of luminal and basal prostate cancer remain unresolved.5,6

10 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MDMatthew P. Deek
Matthew P. Deek
KEKim Van der Eecken
Kim Van der Eecken
PSPhilip Anthony Sutera
Philip Anthony Sutera
RDRebecca A. Deek
Rebecca A. Deek
VFValérie Fonteyne
Valérie Fonteyne
PTPhuoc Tran
Phuoc Tran
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/ 2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.

31 August 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
DQDavid Quigley
David Quigley
JAJoshi J. Alumkal
Joshi J. Alumkal
AWAlexander W. Wyatt
Alexander W. Wyatt
VKVishal Kothari
Vishal Kothari
AFAdam Foye
Adam Foye
FFFelix Y. Feng
Felix Y. Feng
Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2. HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib. In ovarian or breast cancers, olaparib resistance has been associated with HRR restoration, including by BRCA2 mutation reversion. Whether similar mechanisms operate in prostate cancer, and could be detected in liquid biopsies, is unclear. Here, we identify BRCA2 reversion mutations associated with olaparib and talazoparib resistance in patients with prostate cancer. Analysis of circulating cell-free DNA (cfDNA) reveals reversion mutation heterogeneity not discernable from a single solid-tumor biopsy and potentially allows monitoring for the emergence of PARPi resistance. Significance: The mechanisms of clinical resistance to PARPi in DNA repair–deficient prostate cancer have not been described. Here, we show BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib. Furthermore, we show that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PARPi resistance. Cancer Discov; 7(9); 999–1005. ©2017 AACR. See related commentary by Domchek, p. 937. See related article by Kondrashova et al., p. 984. See related article by Goodall et al., p. 1006. This article is highlighted in the In This Issue feature, p. 920